If it can bounce back and generate solid returns in the next five years, now is about as good a time as any to invest in the ...

Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in ...

Thinking about what to do with Recursion Pharmaceuticals stock right now? You are not alone. In just the past week, the stock has jumped an impressive 19.2%, adding to an 18.5% surge over 30 days. It ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $4.98, demonstrating a +1.32% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Best Penny Stocks to Buy with the Highest Upside Potential. On September 10, Gil Blum from Needham reiterated a Buy rating on Recursion ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a clinical-stage biotech, is pioneering the use of artificial intelligence and ...

Technology from computing powerhouse Nvidia is already hard at work inside companies at the convergence of technology and biology, including the supercomputer driving Recursion Pharmaceutical’s drug ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...

Recursion Pharmaceuticals stock soared as much as 121% on Wednesday after it received an investment from Nvidia. Nvidia said it would invest $50 million in the company as it works to use AI for drug ...

On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Dutch Bros (NYSE: BROS). He recommended buying some now and ...

It’s got all the correct buzzwords for a hot biotech stock: machine learning, cell images, artificial intelligence. When Recursion Pharmaceutical went public at $18/share back in April, the stock ...